Tsumura & Co

As the global battle against coronavirus marches on, China's Ping An Insurance is betting that integrated health solutions and traditional Chinese medicines will see strong growth in a post-outbreak w

As China rolls out a massive centralized procurement program to slash prices for many widely-used off-patented drugs, some are seeing market opportunities. Up to now, the generic drug sector in the co

Two weeks after suspension of trading, Zhejiang Hisun Pharmaceutical Co. Ltd. officially addressed enquiries from the Shanghai Stock Exchange regarding the split-up of the Hisun-Pfizer Pharmaceu

Among several bidders for Cardinal Health Inc. ’s China business, Shanghai Pharmaceuticals Holding Co. Ltd. ’s chances to emerge the winner remain uncertain, even as the company has filed its b